Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse | Aplastic Anemia & MDS International Foundation Return to top.

Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse

Journal Title: 
Blood Advances
Primary Author: 
Kent, A
Author(s): 
Andrew Kent, Sumithira Vasu, Derek Schatz, Natalie Monson, Steven Devine, Clayton Smith, Jonathan A Gutman, Daniel A Pollyea
Original Publication Date: 
Tuesday, July 14, 2020

Posttransplantation, glasdegib maintenance therapy in patients at high risk for relapse did not meaningfully reduce relapse incidence.Use of glasdegib in the posttransplantation setting was complicated by adverse events requiring drug holds and occasional discontinuation.

Share with addtoany.com.